SCHEMBL902240

SCHEMBL902240

Oc1c(Cc2ccc(F)c(F)c2)c(C2CC2)nc2ccnn12

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 7/20 0.35
PDE2A O00408 2/20 0.33
CACNA1H O95180 1/20 0.33
MAPKAPK2 P49137 4/20 0.32
CCR5 P51681 2/20 0.32
CDK2 P24941 2/20 0.32
ROCK2 O75116 1/20 0.32
MAPK9 P45984 1/20 0.32
GSK3B P49841 1/20 0.32
MAP2K1 Q02750 1/20 0.32
MAPKAPK5 Q8IW41 1/20 0.32
DPP4 P27487 1/20 0.32
KDM5A P29375 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902644 0.96 PDE2A (0.35) CCR2PDE2AMAPKAPK2CCR5CDK2
SCHEMBL15274712 0.90 PDE4A (0.37) CCR2PDE2AMAPKAPK2CDK2KDM5A
SCHEMBL902384 0.90 CCR2 (0.38) CCR2PDE2AMAPKAPK2CCR5CDK2
SCHEMBL902108 0.90 CCR2 (0.34) CCR2MAPKAPK2CDK2ROCK2MAPK9
SCHEMBL902461 0.88 PDE2A (0.39) CCR2PDE2A
SCHEMBL902690 0.88 PDE2A (0.36) CCR2PDE2A
SCHEMBL901755 0.86 MAPKAPK2 (0.39) CCR2PDE2AMAPKAPK2CCR5CDK2
SCHEMBL15274722 0.86 SLC6A2 (0.34) CCR2PDE2AMAPKAPK2CDK2DPP4
SCHEMBL902442 0.85 CHEK1 (0.34) CCR2PDE2AMAPKAPK2CDK2DPP4
SCHEMBL902632 0.84 PDE4A (0.37) CCR2MAPKAPK2CCR5CDK2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CCR2 1/4885PDE2A 2387/4885CACNA1H 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.